01CONTEXTO
¿Por qué ahora?
AstraZeneca published nine-month and third-quarter results on October 30. Nine-month revenue rose 7% at constant exchange rates to USD46.881bn and reported operating profit reached USD11.797bn, while 12 Phase III programmes produced positive readouts. Yet operating cash inflow fell to USD10.890bn from USD12.233bn and net debt rose to USD25.833bn. The edition therefore tests whether scientific output is becoming durable cash value rather than relying on adjusted earnings alone.
AstraZeneca researches, develops, manufactures and commercialises prescription medicines across Oncology, BioPharmaceuticals and Rare Disease. Revenue is diversified by medicine and geography, but long-term economics depend on patents, clinical success, reimbursement, launch execution and reinvestment in internal and acquired science.
Texto original en inglés · EN
Cuatro fechas distintasAnalysis: November 9, 2026. Latest report period: nine months ended September 30; results and SEC 6-K: October 30. Quote: London Stock Exchange close November 6. FY2025 Form 20-F filed February 24, 2026.
Cotización guardada: 139,30 GBP · 2026-11-06. Cotización obtenida: 2026-11-09T07:14:07Z. London Stock Exchange:AZN · market quote
Fuente financiera revisada y obtenida: 2026-11-09T07:14:07Z.
01
Business model: three therapy engines, one reinvestment loop
For 9M 2026, Oncology generated USD21.889bn, 47% of total revenue, and grew 16% at constant exchange rates. BioPharmaceuticals contributed USD16.731bn and Rare Disease USD7.544bn. The portfolio is therefore broad, but the growth mix is uneven: respiratory and immunology and Rare Disease expanded while CVRM and infectious disease contracted.
The economic moat rests on patents, clinical evidence, regulatory approvals, manufacturing and access rather than a single consumer brand. It must be rebuilt continuously. Internal R&D expense was USD11.439bn in the first nine months, while external licences and acquisitions created a second reinvestment channel outside operating cash flow.
Fuente primaria ↗02
Latest results: reported growth and the cash-flow gap
Nine-month revenue was USD46.881bn, reported operating profit USD11.797bn and profit for the period USD8.705bn. Reported EPS rose 10% and Core EPS 14% at actual exchange rates. Management retained FY2026 guidance for mid-to-high single-digit revenue growth and low-double-digit Core EPS growth at constant exchange rates; this guidance is not used as the model's forecast.
Operating cash inflow fell USD1.343bn year over year to USD10.890bn. The filing attributes the decline chiefly to working capital, Farxiga loss of exclusivity, higher cash tax and currency effects. The result is a useful warning that earnings and cash can diverge during a patent and launch transition.
Fuente primaria ↗03
Debt and capital allocation: flexibility with a rising claim
At September 30, cash and current investments were USD8.166bn, gross debt including leases USD34.191bn and company-defined net debt USD25.833bn, up USD2.459bn since year-end. New long-term borrowing of USD4.972bn exceeded USD2.456bn of repayments. Moody's A1 and S&P A+ long-term ratings were unchanged.
AstraZeneca reported USD12.8bn of financial resources, including USD4.9bn of undrawn committed facilities available to April 2031 and no financial covenants. That supports pipeline funding, but it does not make external R&D free: the return on acquired assets and the refinancing of near-term maturities remain part of the equity risk.
Fuente primaria ↗04
DCF: a conservative post-reinvestment capacity test
The TTM bridge is built only from filed periods: FY2025 less 9M 2025 plus 9M 2026. It produces USD13.232bn of operating cash flow, USD3.463bn of tangible and software capital expenditure, USD0.764bn of share-based payment expense and USD5.276bn of cash spent on acquired intangibles, businesses and contingent consideration. The remaining USD3.729bn is an analytical cash-capacity starting point, not reported free cash flow.
The bear, base and bull cases use different five-year cash growth and equity discount-rate paths. All values are aggregate present values before a complete net-debt, pension, contingent-liability, currency and share-count bridge. A high terminal share is a warning about model duration, not evidence of precision.
Fuente primaria ↗DCF a cinco años: capacidad agregada de generar flujos de caja
Periodo inicial: 2025-10-01 / 2026-09-30 · trailing twelve months. CFO 13,232 USD mil millones − inversión en activos 3,463 USD mil millones − SBC 0,764 USD mil millones − acquired intangibles, businesses and contingent consideration 5,276 USD mil millones = 3,729 USD mil millones.
Valor inicial aproximado de año completo (×1): 3,729 USD mil millones. USD3.729bn is a calculated TTM analytical starting point, not AstraZeneca's reported free cash flow or guidance. Forecast Y1–Y5 begins after September 30, 2026.
Fórmula: PV = Σ CFₜ/(1+kₑ)ᵗ + CF₅(1+g)/(kₑ−g)/(1+kₑ)⁵. El crecimiento del flujo de caja neto incorpora la reinversión continuada, la remuneración en acciones y el capital circulante. El crecimiento terminal supone una generación sostenible de caja neta después de esos costes.
Escenario base · años del modelo posteriores a la fecha del análisis| Año | Crecimiento | Flujo de caja | Valor presente |
|---|
| Y1 | 8% | 4,027 USD mil millones | 3,712 USD mil millones |
|---|
| Y2 | 7% | 4,309 USD mil millones | 3,661 USD mil millones |
|---|
| Y3 | 6% | 4,568 USD mil millones | 3,576 USD mil millones |
|---|
| Y4 | 5% | 4,796 USD mil millones | 3,461 USD mil millones |
|---|
| Y5 | 4% | 4,988 USD mil millones | 3,317 USD mil millones |
|---|
Escenarios · supuestos analíticos, sin probabilidades asignadas| Escenario | kₑ / g | Crecimiento a cinco años | Valor actual de los flujos de caja | Peso del valor terminal |
|---|
| Pesimista | 10% / 1,5% | -5% → 0% → 2% → 2% → 2% | 41,589 USD mil millones | 67,02% |
|---|
| Base | 8,5% / 2,5% | 8% → 7% → 6% → 5% → 4% | 74,396 USD mil millones | 76,17% |
|---|
| Optimista | 7,5% / 3% | 12% → 11% → 9% → 7% → 5% | 110,481 USD mil millones | 81,93% |
|---|
Pesimista: Patent erosion, slower reimbursement and further external portfolio spending absorb launch growth; a higher required return reflects clinical and capital-allocation risk.
Base: Oncology, respiratory/immunology and rare-disease launches more than offset mature-product decline, while post-reinvestment cash growth fades toward a mature pharmaceutical rate.
Optimista: Multiple late-stage assets reach broad labels and commercial scale, working capital recovers and external R&D spending produces stronger cash productivity.
Aggregate levered cash capacity after interest, tax and disclosed productive/external portfolio reinvestment. No per-share target or separate release of cash is asserted; debt, leases, pensions, contingent liabilities, currency and diluted shares require a separate equity bridge.